Progyny stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 66 to 73.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily measures share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves. See if Progyny stock can continue to show renewed price strength and clear that threshold.
Is Progyny Stock A Buy?
Progyny stock is working on a consolidation with a 26.76 entry. See if it can break out in volume at least 40% higher than normal. Given current stock market uncertainties, IBD recommends a cautious 20-40% market exposure. Be judicious with stock purchases.
The women's benefits solutions company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 5% to 31%. Revenue rose from 2% to 11%. Progyny is expected to report its latest earnings and sales numbers on or around May 8.
Progyny stock holds the No. 6 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Option Care Health and iRhythm Technologies are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
